Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Introducing the Finviz Matrix

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Cingulate Inc.

Contributing Author

Recent Articles by Cingulate Inc.

Aug-13
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness CING GlobeNewswire
Aug-11
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301's Differentiated Pharmacokinetic Profile CING GlobeNewswire
Jul-30
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology CING +5.19% GlobeNewswire
Jul-02
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E CING -8.66% GlobeNewswire
Jun-16
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301 CING GlobeNewswire
Jun-02
Cingulate Receives Complete Response Letter from FDA for CTx-1301 CING +11.94% GlobeNewswire
May-14
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301 CING -10.77% GlobeNewswire
Mar-18
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights CING -31.05% GlobeNewswire
Feb-17
Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules CING GlobeNewswire
Nov-13
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update CING -12.37% GlobeNewswire
Nov-10
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301 CING GlobeNewswire
Oct-28
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control CING GlobeNewswire
Oct-23
Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting CING CING +7.82% GlobeNewswire
Oct-14
FDA Accepts Cingulate's New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date CING GlobeNewswire
Sep-17
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment CING -5.85% GlobeNewswire
Aug-19
Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights CING -9.62% GlobeNewswire
Aug-15
Cingulate Provides Management Team Update CING GlobeNewswire
Aug-06
Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301 CING -16.61% GlobeNewswire
Jul-29
Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301 CING GlobeNewswire
Jul-09
Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application CING GlobeNewswire
May-20
Efficacy Results Announced from Cingulate's Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD CING GlobeNewswire
May-14
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301 CING +8.70% GlobeNewswire
May-08
Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets CING GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)